A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumors
What is the purpose of this trial?
This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase in patients with advanced solid tumors.
- Years and older
- MedImmune, Inc
- Last Updated:
- Study HIC#: